Occlutech was founded in Germany in 2003, and has since developed into one of the world´s leading suppliers in the area of structural heart disease with products and projects for; congenital defects, stroke prevention, and heart failure.
Occlutech PFO closure device: a long-term (up to 10-year overview) review of safety and efficacy Developed as part of a dedicated partnership between Occlutech and Radcliffe Cardiology, the following short video delivers exclusive insight into first of its kind research conducted by Dr Daniela Trab...
Comparative study showed that the Occlutech ASD Occluder is associated with shorter procedure time (p= 0.166) and less radiation (p= 0.001).7 The ball-connector of the Occlutech ASD Occluder provides free rotation and force-free angulation up to 50 degrees and therefore facilitates implantation, ...
The human heart comprises 4 “chambers”: two upper chambers known as the “atria” and two lower chambers known as the “ventricles”.The right side of the heart comprises the right atrium (RA) and right ventricle (RV). The left side comprises the left atrium (LA) and left ventricle (...
瑞士沙夫豪森2021年6月2日 /美通社/ -- Occlutech AG(以下简称“Occlutech”或“公司”)宣布在中国进行的心房中隔缺损封堵器(ASD Occluder)试验已招募180名患者。Occlutech ASD Occluder是一种用于治疗先天性心脏疾病心房中隔缺损(ASD)封堵器。完成患者招募是Occlutech在中国申请心房中隔缺损封堵器批准流程中的一个重要...
(医药健闻2021年8月16日讯) Occlutech Holding AG,全球领先的微创结构性心脏病器械提供商之一,宣布其进行关键研究OCCLUFLEX的研究器械豁免(IDE)申请获得有条件的美国食品和药物管理局(“FDA”)批准,该研究将利用Occlutech的Flex II PFO封堵器完成的卵圆孔未闭(“PFO”)闭合术与隐源性卒中患者PFO封堵术的护理标准进...
Occlutech AG宣布,其心房分流器Occlutech AFR已获得CE认证,可以在欧洲CE监管市场上销售。Occlutech AFR是一种新一代心房内分流装置,旨在通过解除异常心房内压来治疗心力衰竭症状,可通过一种微创手术放置在左心房和右心房之间的隔膜处,具有不同的尺寸,因而支持独特的病人导向和个体化治疗。
瑞士沙夫豪森2021年5月3日 /美通社/ -- Occlutech Holding AG（以下简称“Occlutech”）今天宣布Marianne Dicander Alexandersson、Mette-Marie Harild、Helena Levander和Michel Lussier当选为Occlutech董事会成员。在2021年6月18日举行的年度股东大会上，Marianne Dicander Alexandersson将被提名为Occlutech董事会主席。“...
近日,全球领先的微创结构性心脏病器械提供商之一Occlutech Holding AG(以下简称“Occlutech”),宣布其进行关键研究OCCLUFLEX的研究器械豁免(IDE)申请获得有条件的美国食品和药物管理局(“FDA”)批准,该研究将利用Occlutech的Flex II PFO封堵器完成的卵...
最近,Occlustech宣布,美国食品和药物管理局(FDA)已经授予其产品可植入心房流量调节器(AFR)突破性器械认定,用于治疗射血分数保留(HFpEF)或降低(HFrEF)的心力衰竭(HF)患者。 AFR适用于药物治疗后病情仍持续恶化射血分数保持(HFpEF)或射血分数降低(HFrEF)的心力...